{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:25:05Z","timestamp":1786965905401,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114644","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:40:02Z","timestamp":1786963202000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Effectiveness of Roflumilast in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Nithin","family":"Sai Yenugu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Bin","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Disha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shramik","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heer","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonalben","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsha","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed A","year":"2023","unstructured":"Agust\u00ed A, Celli BR, Criner GJ, et al.. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023, 207:819-37. 10.1164\/rccm.202301-0106PP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst JR","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, et al.. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363:1128-38. 10.1056\/NEJMoa0909883","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha JA","year":"2007","unstructured":"Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007, 370:786-96. 10.1016\/S0140-6736(07)61382-8","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe KF","year":"2011","unstructured":"Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011, 163:53-67. 10.1111\/j.1476-5381.2011.01218.x","journal-title":"Br J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg JC","year":"2004","unstructured":"Hogg JC, Chu F, Utokaparch S, et al.. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350:2645-53. 10.1056\/NEJMoa032158","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard SI","year":"2011","unstructured":"Rennard SI, Calverley PM, Goehring UM, Bredenbr\u00f6ker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011, 12:18. 10.1186\/1465-9921-12-18","journal-title":"Respir Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri LM","year":"2009","unstructured":"Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al.. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009, 374:695-703. 10.1016\/S0140-6736(09)61252-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1252","article-title":"Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study","volume":"145","author":"Zheng J","year":"2014","unstructured":"Zheng J, Yang J, Zhou X, et al.. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014, 145:44-52. 10.1378\/chest.13-1252","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez FJ","year":"2015","unstructured":"Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015, 385:857-66. 10.1016\/S0140-6736(14)62410-7","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002309.pub4","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong J","year":"2013","unstructured":"Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013, CD002309. 10.1002\/14651858.CD002309.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2013.04.004","article-title":"Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis","volume":"27","author":"Yan JH","year":"2014","unstructured":"Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014, 27:83-9. 10.1016\/j.pupt.2013.04.004","journal-title":"Pulm Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast\u2014an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe KF","year":"2005","unstructured":"Rabe KF, Bateman ED, O\u2019Donnell D, Witte S, Bredenbr\u00f6ker D, Bethke TD. Roflumilast\u2014an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005, 366:563-71. 10.1016\/S0140-6736(05)67100-0","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells GA","year":"2000","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Semantic Scholar. 2000,","journal-title":"Semantic Scholar"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00011714","article-title":"The effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients","volume":"44","author":"De Backer W","year":"2014","unstructured":"De Backer W, Vos W, Van Holsbeke C, et al.. The effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients. Eur Respir J. 2014, 44:527-9. 10.1183\/09031936.00011714","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.110036","article-title":"Effectiveness of oral roflumilast among chronic obstructive pulmonary disease patients to prevent exacerbations","volume":"18","author":"Laique T","year":"2026","unstructured":"Laique T, Latif H, Khan MZ, et al.. Effectiveness of oral roflumilast among chronic obstructive pulmonary disease patients to prevent exacerbations. Cureus. 2026, 18:e110036. 10.7759\/cureus.110036","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2011.02038.x","article-title":"Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial","volume":"16","author":"Lee S","year":"2011","unstructured":"Lee S, Hui DS, Mahayiddin AA, et al.. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology. 2011, 16:1249-57. 10.1111\/j.1440-1843.2011.02038.x","journal-title":"Respirology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2025.61.3.129","article-title":"Effects of roflumilast on exacerbations and lung function in COPD patients with bronchiectasis","volume":"61","author":"Lee JK","year":"2025","unstructured":"Lee JK, Yoon CS, Kho BG, et al.. Effects of roflumilast on exacerbations and lung function in COPD patients with bronchiectasis. Chonnam Med J. 2025, 61:129-35. 10.4068\/cmj.2025.61.3.129","journal-title":"Chonnam Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009864","article-title":"Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients","volume":"97","author":"Liu DY","year":"2018","unstructured":"Liu DY, Wang ZG, Gao Y, Zhang HM, Zhang YX, Wang XJ, Peng D. Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients. Medicine. 2018, 97:e9864. 10.1097\/MD.0000000000009864","journal-title":"Medicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201612-2518LE","article-title":"Randomized double-blind controlled trial of roflumilast at acute exacerbations of chronic obstructive pulmonary disease","volume":"196","author":"Mackay AJ","year":"2017","unstructured":"Mackay AJ, Patel AR, Singh R, et al.. Randomized double-blind controlled trial of roflumilast at acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017, 196:656-9. 10.1164\/rccm.201612-2518LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE\u00b2SPOND): a randomized clinical trial","volume":"194","author":"Martinez FJ","year":"2016","unstructured":"Martinez FJ, Rabe KF, Sethi S, et al.. Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE\u00b2SPOND): a randomized clinical trial. Am J Respir Crit Care Med. 2016, 194:559-67. 10.1164\/rccm.201607-1349OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00096511","article-title":"Physiological effects of roflumilast at rest and during exercise in COPD","volume":"39","author":"O\u2019Donnell DE","year":"2012","unstructured":"O\u2019Donnell DE, Bredenbr\u00f6ker D, Brose M, Webb KA. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012, 39:1104-12. 10.1183\/09031936.00096511","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","volume":"187","author":"Vestbo J","year":"2013","unstructured":"Vestbo J, Hurd SS, Agust\u00ed AG, et al.. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 187:347-65. 10.1164\/rccm.201204-0596PP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0218PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary","volume":"195","author":"Vogelmeier CF","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, et al.. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017, 195:557-82. 10.1164\/rccm.201701-0218PP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst DC","year":"2007","unstructured":"Grootendorst DC, Gauw SA, Verhoosel RM, et al.. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007, 62:1081-7. 10.1136\/thx.2006.075937","journal-title":"Thorax"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2014.08.18","article-title":"Diagnosis and early detection of COPD using spirometry","volume":"6","author":"Johns DP","year":"2014","unstructured":"Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using spirometry. J Thorac Dis. 2014, 6:1557-69. 10.3978\/j.issn.2072-1439.2014.08.18","journal-title":"J Thorac Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S154012","article-title":"Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD","volume":"13","author":"Watz H","year":"2018","unstructured":"Watz H, Bagul N, Rabe KF, et al.. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Int J Chron Obstruct Pulmon Dis. 2018, 13:813-22. 10.2147\/COPD.S154012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-40","article-title":"Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review","volume":"12","author":"Westwood M","year":"2011","unstructured":"Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011, 12:40. 10.1186\/1465-9921-12-40","journal-title":"Respir Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725080-00007","article-title":"A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease","volume":"25","author":"Rutten-van M\u00f6lken MP","year":"2007","unstructured":"Rutten-van M\u00f6lken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007, 25:695-711. 10.2165\/00019053-200725080-00007","journal-title":"Pharmacoeconomics"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1395","article-title":"Drug safety in COPD revisited: What is the number needed to analyze?","volume":"142","author":"Rabe KF","year":"2012","unstructured":"Rabe KF. Drug safety in COPD revisited: What is the number needed to analyze?. Chest. 2012, 142:271-4. 10.1378\/chest.12-1395","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522438-clinical-effectiveness-of-roflumilast-in-patients-with-chronic-obstructive-pulmonary-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:40:03Z","timestamp":1786963203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522438-clinical-effectiveness-of-roflumilast-in-patients-with-chronic-obstructive-pulmonary-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.114644","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}